SYNAGEVA BIOPHARMA CORP's ticker is GEVA and the CUSIP is 87159A103. A total of 127 filers reported holding SYNAGEVA BIOPHARMA CORP in Q4 2014. The put-call ratio across all filers is 1.42 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2014 | $622,000 | – | 6,700 | – | 0.60% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Baker Brothers Advisors | 9,223,182 | $387,189,000 | 7.66% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 78,486 | $3,295,000 | 0.56% |
| COLUMBIA WANGER ASSET MANAGEMENT LLC | 2,485,288 | $104,382,000 | 0.46% |
| HARVEY CAPITAL MANAGEMENT INC | 34,800 | $1,460,000 | 0.45% |
| EMERALD ADVISERS, LLC | 148,232 | $6,223,000 | 0.38% |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 148,411 | $6,233,000 | 0.27% |
| ArrowMark Colorado Holdings LLC | 15,500 | $651,000 | 0.18% |
| CR Intrinsic Investors, LLC | 118,161 | $4,963,000 | 0.17% |
| BB BIOTECH AG | 53,549 | $2,248,000 | 0.16% |
| TURNER INVESTMENTS LLC | 209,744 | $8,806,000 | 0.12% |